November 12, 2021

Dear AVAC supporter,

Founded more than 25 years ago to spur the development of preventive HIV vaccines, AVAC is a respected voice in the global response to HIV/AIDS. We have established trusted and durable relationships with a wide spectrum of stakeholders—from civil society advocates to policy makers, industry to academics, product developers to program implementers, donors to the media, and beyond.

Since those early days of vaccine advocacy, we have expanded our approach to include accelerating the development and introduction of a wide range of HIV prevention options as well as related research areas including sexual and reproductive health, TB and COVID-19, underscoring the need for a comprehensive, integrated, and sustained agenda to refine the pathway from product development to user and, ultimately, to help end epidemics.

We are advocates, translators and catalyzers. AVAC serves as a source of information and plays an invaluable role in translating complex science so that it is accessible to advocates, communities, the media and decision makers. In parallel, AVAC plays an instrumental role in elevating and amplifying community perspectives among scientists, industry leaders, policy makers and the media to ensure that innovative, user-centered prevention options are developed ethically and delivered expeditiously and equitably.

Today, AVAC is poised to deepen engagement at the global level and simultaneously work in service of country needs while strengthening the capacity of advocates and institutions by pushing for ethical development of and equitable access to innovative HIV prevention and related pandemic response options, while leveraging these practices to contribute more broadly to global health equity.

Our financial position reflects the successful past and future sustainability of AVAC. The numbers on this page clearly show we are well-positioned for the future. We continue to receive strong, multi-year support from major funders and governments, continually educate and enhance our professional staff, and are ready to face new challenges and opportunities as they arise. Over the past two years, we have greatly increased the number of donors to AVAC, including major new grants from the Rockefeller Foundation, Children’s Investment Fund Foundation, and the US NIH via the Martin Delaney Collaboratories for HIV Cure Research (MDC), among others. This growing support represents both our financial diversification and the wise investment that the AVAC agenda represents.

We are proud that vast majority of our resources – in 2020 86% of the total budget was devoted to our programs, with relatively small amounts on finance, administration and fundraising. This means that 86 cents of every dollar donated to AVAC went toward our policy, advocacy, communications, education and outreach work. We are proud of our sustainable growth, our impact on the HIV epidemic, and our role in advancing global health equity.

AVAC remains committed to the values on which we were founded. Advocates and community members must continue to play a leading role in defining research and implementation agendas. Achieving global health equity will take all of us.

Many thanks for your support,

David Cook
Treasurer

Accelerating the ethical development and global delivery of HIV prevention options as part of a comprehensive, integrated and sustained response to the epidemic

540 President St.
3rd Floor
Brooklyn, NY 11215
USA

T +1 212 796 6423
F +1 646 365 3452
E avac@avac.org
W www.avac.org